贝伐珠单抗联合培美曲塞及铂类化疗对老年晚期肺腺癌患者的疗效观察OA

Objective:To explore the effects of bevacizumab,pemetrexed combined with platinum-based chemotherapy on efficacy,immune function and programmed death ligand 1(PD-L1)expression in elderly patients with advanced lung adenocarcinoma.Methods:Retrospectively,the clinical data of 100 elderly patients with advanced lung adenocarcinoma who were diagnosed and treated at a hospital from January 2022 to February 2023 and followed up until March 2025 were selected as study subjects.According to different treatment plans,they were divided into the combined group(administering bevacizumab,pemetrexed combined with platinum-based chemotherapy,n=48)and the control group(administering pemetrexed combined with platinum-based chemotherapy,n=52).T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),natural killer cell(NK cell)activity,tumor markers[tumor-specific growth factor(TSGF),carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],PD-L1,and clinical efficacy expression were compared between the two groups.Overall survival(OS),progression free survival(PFS),survival rate,and progression-free survival rate were observed.Results:After treatment,the decreases in CD3+,CD4+,CD4+/CD8+levels and NK cell activity in the combined group were smaller than those in the control group,and the levels of TSGF,CEA,CYFRA21-1,and PD-L1 were lower than those in the control group(P<0.05).The objective response rate(ORR)and disease control rate(DCR)of the combined group were higher than those of the control group(P<0.05).The 2-year OS and PFS of the combined group were longer than those of the control group,and the 1-year and 2-year OS rates and PFS rates were higher than those of the control group(P<0.05).Conclusion:The combination of bevacizumab,pemetrexed and platinum-based chemotherapy has a relatively ideal effect in treating elderly patients with advanced lung adenocarcinoma.It helps to reduce tumor markers and PD-L1 levels,prolong patient survival,and has a minor impact on immune function.